Predicting Effective Therapy in Pancreatic Cancer
NCT03033927 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 74
Last updated 2026-04-27
Summary
The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
CTC isolocation and analysis
Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.
Sponsors & Collaborators
-
Memorial Sloan Kettering Cancer Center
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-01-24
- Primary Completion
- 2027-01-24
- Completion
- 2027-01-24
Countries
- United States
Study Locations
More Related Trials
-
Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel
NCT06043921 ·Status: RECRUITING
-
Evaluating the Response to Neoadjuvant Chemotherapy With Circulating Tumor DNA in Pancreatic Cancer
NCT04616131 ·Status: UNKNOWN
-
Determining Individualized Cancer Therapy in Pancreatic Cancer
NCT05914987 ·Status: RECRUITING
-
The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma
NCT06807112 ·Status: NOT_YET_RECRUITING
-
Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer
NCT07326150 ·Status: ACTIVE_NOT_RECRUITING
-
Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy
NCT07122466 ·Status: ACTIVE_NOT_RECRUITING
-
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
NCT04281511 ·Status: COMPLETED
-
Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx
NCT00767273 ·Status: COMPLETED ·Phase: NA
-
Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients
NCT02767557 ·Status: COMPLETED ·Phase: PHASE2
-
Role of Perfusion CT in Pancreatic Cancer
NCT01703650 ·Status: UNKNOWN
-
Application of ctDNA in Evaluation of Neoadjuvant Chemotherapy Efficacy and Exploration of Chemoresistance Mechanisms in Pancreatic Cancer
NCT05848154 ·Status: NOT_YET_RECRUITING
-
Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC
NCT03032913 ·Status: COMPLETED
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
NCT03322995 ·Status: RECRUITING ·Phase: PHASE2
-
Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients
NCT02707159 ·Status: COMPLETED ·Phase: PHASE2
-
Studying Biomarkers in Patients With Pancreatic Cancer
NCT00900003 ·Status: COMPLETED
-
Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer
NCT00805688 ·Status: COMPLETED
-
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
NCT03983057 ·Status: COMPLETED ·Phase: PHASE2
-
Optical and Biochemical Biomarkers in Early Pancreatic Cancer
NCT03404661 ·Status: COMPLETED
-
Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
NCT07096362 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer
NCT00003332 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer
NCT00897832 ·Status: COMPLETED
-
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT02754726 ·Status: COMPLETED ·Phase: PHASE2
-
CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
NCT03851237 ·Status: COMPLETED ·Phase: PHASE1
-
Circulating Cell-free Tumor DNA(ctDNA) in Pancreatic Cancer
NCT02934984 ·Status: UNKNOWN
-
RNA Precision Oncology in Advanced Pancreatic Cancer
NCT04476537 ·Status: TERMINATED ·Phase: NA